2:26 PM
 | 
Apr 16, 2018
 |  BC Extra  |  Clinical News

NewLink re-evaluating Phase III plans for indoximod combo

NewLink Genetics Corp. (NASDAQ:NLNK) said Sunday that it will not start the randomized, placebo-controlled portion of the Phase III Indigo301 trial to evaluate indoximod (NLG8189) plus anti-PD-1 mAbs Keytruda pembrolizumab or Opdivo nivolumab to treat unresectable or metastatic melanoma. The company had planned to start the randomized portion of the trial in 2Q18 or 3Q18. Indoximod is an indoleamine 2,3-dioxygenase (INDO; IDO) pathway inhibitor.

The news comes...

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >